Corporate & Investor Presentation

There is a need for end-to-end solutions for COPD patients Global population of COPD patients: ~380 million¹ Self-management (smoking cessation, diet, exercise) Inhaled Pharmaceuticals for COPD High Flow Therapy and/or Oxygen Ventilation 75% of pop. Stage II Increasing severity of disease COPD progression Stage I 18 2021 ResMed | Corporate & Investor Presentation - updated 29APR21 1. Adeloye D et al. J Glob Health 2015 20% of pop. <1% of pop. Stage III Stage IV ResMed

View entire presentation